<?xml version="1.0" encoding="UTF-8"?>
<p id="p0075">We believe that there is sufficient evidence to support clinical trials combining IL-6R antagonists with PD-1 inhibitors to improve outcomes in patients with COVID-19. We propose that an earlier intervention with antiâ€“PD-1 therapy will minimise the need for intensive care support.</p>
